| Literature DB >> 23826308 |
Sasha E Parets1, Karen N Conneely, Varun Kilaru, Stephen J Fortunato, Tariq Ali Syed, George Saade, Alicia K Smith, Ramkumar Menon.
Abstract
Spontaneous preterm birth (PTB, <37 weeks gestation) is a major public health concern, and children born preterm have a higher risk of morbidity and mortality throughout their lives. Recent studies suggest that fetal DNA methylation of several genes varies across a range of gestational ages (GA), but it is not yet clear if fetal epigenetic changes associate with PTB. The objective of this study is to interrogate methylation patterns across the genome in fetal leukocyte DNA from African Americans with early PTB (24(1/7)-34(0/7) weeks; N = 22) or term births (39(0/7)-40(6/7)weeks; N = 28) and to evaluate the association of each CpG site with PTB and GA. DNA methylation was assessed across the genome with the HumanMethylation450 BeadChip. For each individual sample and CpG site, the proportion of DNA methylation was estimated. The associations between methylation and PTB or GA were evaluated by fitting a separate linear model for each CpG site, adjusting for relevant covariates. Overall, 29 CpG sites associated with PTB (FDR<.05; 5.7×10(-10)<p<2.9×10(-6)) independent of GA. Also, 9637 sites associated with GA (FDR<.05; 9.5×10(-16)<p<1.0×10(-3)), with 61.8% decreasing in methylation with shorter GA. GA-associated CpG sites were depleted in the CpG islands of their respective genes (p<2.2×10(-16)). Gene set enrichment analysis (GSEA) supported enrichment of GA-associated CpG sites in genes that play a role in embryonic development as well as the extracellular matrix. Additionally, this study replicated the association of several CpG sites associated with gestational age in other studies (CRHBP, PIK3CD and AVP). Dramatic differences in fetal DNA methylation are evident in fetuses born preterm versus at term, and the patterns established at birth may provide insight into the long-term consequences associated with PTB.Entities:
Mesh:
Year: 2013 PMID: 23826308 PMCID: PMC3694903 DOI: 10.1371/journal.pone.0067489
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Clinical and demographic characteristics of the cohort.
| Phenotype | PTB (N = 22) | Term Birth (N = 28) | p-value |
| Mean±SD | Mean +/− SD | ||
| Male, % | (14) 63.6% | (11) 39.3% | NS |
| Gestational age, weeks | 30.8±3.3 | 39.8±0.4 | <.0001 |
| Birthweight, grams | 1524.1±638.1 | 3304.9±333.4 | <.0001 |
| Birthweight percentile | 32±27.7 | 47±25.3 | NS |
| Gravidity | 2.2±1.5 | 2.4±2.7 | NS |
| Maternal Age | 25.5±5.2 | 21.0±4.6 | NS |
| Employed | (5) 22.7% | (8) 36.3% | NS |
| Married | (7) 35.0% | (7) 25.0% | NS |
| Maternal Smoking | (5) 22.7% | (5) 17.9% | NS |
| Income | |||
| <15 K | (12) 54.5% | (12) 42.9% | |
| 15–30 K | (5) 22.7% | (8) 28.5% | NS |
| >30 K | (5) 22.7% | (8) 28.5% |
All subjects are African American.
NS indicates the p-value is not significant (p>.05).
infection
, birth weight percentile, and gravidity (data not shown) nor were they altered by logit-transformation of the beta values. Among the CpG sites associated with PTB, we observed increased DNA methylation of a site (cg13250001) in GSK3B (glycogen synthase kinase 3 beta; p = 1.7×10−6; Δβ = −.06) and decreased methylation of a CpG site (cg25376491) in MAML1 (mastermind-like 1; p = 1.8×10−6; Δβ = .14) in fetuses with PTB. In addition, 3 other CpG sites in GSK3B and 4 in MAML1 were nominally associated with PTB (p<.05).
Figure 1Manhattan plots depicting the association of all CpG sites with (A) PTB and with (B) GA.
The y-axis is the negative log10 of the p-value for the association while the x-axis is position on each chromosome. The dashed line indicates experiment-wide significance. Genomic locations of each CpG site are in Table S1.
29 CpG sites that associated with PTB (adjusted for GA).
| Probe ID | Gene | Δβ | t-statistic | p-value |
| cg04549583 | −0.133 | −8.30 | 5.70×10−10 | |
| cg13290254 | 0.122 | 7.52 | 5.77×10−9 | |
| cg03254336 | 0.178 | 6.87 | 4.24×10−8 | |
| cg16447680 |
| −0.131 | −6.60 | 9.84×10−8 |
| cg03272932 | 0.175 | 6.54 | 1.19×10−7 | |
| cg03152187 |
| −0.112 | −6.15 | 3.91×10−7 |
| cg18721397 |
| 0.259 | 6.12 | 4.31×10−7 |
| cg03706951 | −0.142 | −6.04 | 5.57×10−7 | |
| cg13514049 | 0.129 | 6.01 | 6.13×10−7 | |
| cg01142526 |
| −0.049 | −5.92 | 8.00×10−7 |
| cg03901454 | 0.174 | 5.86 | 9.65×10−7 | |
| cg19787650 |
| 0.181 | 5.85 | 9.88×10−7 |
| cg20253872 |
| −0.174 | −5.85 | 1.00×10−6 |
| cg06320380 |
| −0.111 | −5.79 | 1.20×10−6 |
| cg23471393 | 0.185 | 5.79 | 1.23×10−6 | |
| cg26501007 | 0.135 | 5.75 | 1.38×10−6 | |
| cg13250001 |
| −0.062 | −5.68 | 1.70×10−6 |
| cg20519581 | 0.224 | 5.68 | 1.73×10−6 | |
| cg04212285 |
| 0.155 | 5.67 | 1.75×10−6 |
| cg25376491 |
| 0.14 | 5.66 | 1.82×10−6 |
| cg00101629 |
| 0.147 | 5.65 | 1.86×10−6 |
| cg19921917 |
| 0.177 | 5.61 | 2.15×10−6 |
| cg12207930 |
| 0.198 | 5.59 | 2.24×10−6 |
| cg10131972 |
| −0.077 | −5.59 | 2.25×10−6 |
| cg09964921 | 0.162 | 5.57 | 2.44×10−6 | |
| cg01476222 |
| 0.144 | 5.56 | 2.49×10−6 |
| cg03318906 |
| 0.128 | 5.54 | 2.60×10−6 |
| cg01621943 | 0.185 | 5.54 | 2.65×10−6 | |
| cg13749927 |
| −0.070 | −5.51 | 2.91×10−6 |
Δβ represents the average methylation difference between early PTB and term birth after adjustment for covariates.
children
[29].Enrichment analysis to examine whether there is a an enrichment in certain regions that associated with GA, or whether there is an enrichment of a certain direction of a t-statistic for associated CpG sites.
| GA-associated | Not GA-associated | p-value | (+) GA-associated | (−) GA-associated | p-value | |
| CpG Islands | 14.9% | 31.3% | <2.2×10−16 | 18.4% | 9.4% | <2.2×10−16 |
| CpG Shores | 34.1% | 22.8% | <2.2×10−16 | 33.4% | 35.2% | NS |
| Promoter | 22.9% | 25.0% | 2.5×10−6 | 25.3% | 18.7% | 4.7×10−14 |
| 5′ UTR | 10.1% | 8.8% | 6.0×10−6 | 8.6% | 12.5% | 1.7×10−9 |
| 1st Exon | 3.1% | 4.7% | 4.7×10−15 | 3.0% | 3.3% | NS |
| Gene Body | 35.0% | 33.3% | 4.4×10−4 | 29.6% | 43.7% | <2.2×10−16 |
| 3′ UTR | 2.9% | 3.6% | <2.2×10−16 | 2.1% | 4.3% | 1.5×10−9 |
| Intragenic | 26.0% | 24.6% | .003 | 31.4% | 17.1% | <2.2×10−16 |
Note that each row in the table represents a Fisher’s exact test that tests for enrichment of associated or unassociated sites for the relevant category (e.g. CpG islands).
NS indicates the p-value is not significant (p>.05).
HDAC4
is involved in numerous identified pathways including system development and multicellular organismal development, anatomical structure development, organ development, and nervous system development. Several other CpG sites involved in epigenetic regulation during development were also identified. Specifically, CpG sites in the gene body of DNMT1 (DNA methyltransferase 1; p = 3.4×10−5; t = −4.7; Δβ per week = −.0034), the gene body of DNMT3A (p = 6.7×10−4; t = −3.7; Δβ per week = −.0042), the 5′UTR of DNMT3B (4.5×10−6TET1 (tet methylcytosine dioxygenase 1; 1.5×10−7
Gene enrichment analysis of CpG sites that associated with GA (FDR<.05).
| GO Term: Biological Processes | Size | NES | FDR q-value |
| Neuron differentiation | 29 | 2.69 | 0.001 |
| Generation of neurons | 33 | 2.53 | 0.003 |
| Multicellular organismal development | 307 | 2.39 | 0.006 |
| Anatomical structure development | 309 | 2.32 | 0.007 |
| System development | 258 | 2.24 | 0.011 |
| Neurogenesis | 34 | 2.23 | 0.011 |
| Cellular morphogensis during differentiation | 16 | 2.17 | 0.014 |
| Neuron development | 20 | 2.09 | 0.023 |
| Embryonic development | 24 | 2.08 | 0.022 |
| Organ development | 171 | 2.04 | 0.026 |
| Nervous system development | 133 | 2 | 0.033 |
| Skeletal development | 34 | 1.95 | 0.042 |
| Anatomical structure morphogenesis | 122 | 1.9 | 0.048 |
| Negative regulation of biological process | 183 | −2.18 | 0.043 |
| Apoptosis GO | 127 | −2.17 | 0.036 |
| Positive regulation of I-kappaB kinase NF-kappaB cascade | 23 | −2.13 | 0.042 |
|
| |||
| Extracellular region part | 75 | 3.13 | <.001 |
| Extracellular region | 97 | 3.02 | <.001 |
| Extracellular space | 48 | 2.66 | <.001 |
| Proteinaceous extracellular matrix | 26 | 2.24 | 0.009 |
| Extracellular matrix | 26 | 2.2 | 0.009 |
| Extracellular matrix part | 20 | 2.05 | 0.017 |
| Intracellular organelle part | 219 | −2.12 | 0.042 |
| Organelle part | 219 | −2.12 | 0.021 |
| Nuclear part | 102 | −2.08 | 0.019 |
| Microtubule cytoskeleton | 37 | −2.03 | 0.023 |
| Nucleus | 313 | −2.02 | 0.02 |
| Ribonucleoprotein complex | 17 | −1.97 | 0.026 |
| Membrane enclosed lumen | 73 | −1.93 | 0.029 |
| Cytoskeletal part | 53 | −1.93 | 0.025 |
| Nuclear lumen | 66 | −1.92 | 0.023 |
| Organelle lumen | 73 | −1.91 | 0.023 |
| Cytoskeleton | 105 | −1.9 | 0.022 |
| Nucleoplasm | 56 | −1.87 | 0.025 |
| Nucleoplasm part | 37 | −1.79 | 0.038 |
| Cell cortex | 16 | −1.74 | 0.048 |
| Non membrane bound organelle | 138 | −1.73 | 0.047 |
| Intracellular non membrane bound organelle | 138 | −1.73 | 0.046 |
| Macromolecular complex | 166 | −1.71 | 0.049 |
NES is the normalized enrichment score.
MMP9
is involved in the breakdown of the extracellular matrix in the process of cervical ripening, and increased expression has been seen in pPROM compared to preterm birth with intact membranes [32]. Further, 1 CpG site in the gene body of the MMP9 inhibitor, TIMP2 also associates with GA (p = 1.4×10−5; t = −5.0; Δβ per week = −.0053).corticotrophin-releasing hormone binding protein
(CRHBP) increased with decreasing GA (t = −4.49; p = 6.5×10−5; Δβ per week = .01). CRHBP regulates corticotrophin-releasing hormone (CRH), a principal regulator of the hypothalamic-pituitary-adrenal (HPA) axis. In addition, methylation increased in a CpG site in the promoter of PIK3CD (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit delta) with decreasing GA (p = 2.4×10−8; t = −7.0; Δβ per week = −.0062). The therapeutic value of PIK3CD inhibitors is currently being explored as anti-inflammatory drugs [33].Replication of CpG sites previously associated with GA [18].
| Probe ID | Gene | Δβ per week | t-statistic | p-value |
| cg09523691 |
| −.0030 | −3.33 | .0020 |
| cg16536918 |
| −.0065 | −3.08 | .0039 |
| cg25551168 |
| −.0067 | −3.61 | 8.7×10−4 |
| cg01143454 |
| −.0034 | −1.66 | .10 |
| cg26799474 |
| −.0087 | −4.03 | 2.6×10−4 |
| cg13813391 |
| −.0067 | −3.99 | 2.9×10−4 |
| cg21842274 |
| −.014 | −4.49 | 6.5×10−5 |
| cg11540997 |
| .0032 | 3.27 | .0023 |
| cg14409083 |
| −.0052 | −3.00 | .0047 |
| cg15626350 |
| .011 | 3.83 | 4.6×10−4 |
| cg20291222 |
| −.0065 | −3.63 | 8.4×10−4 |
| cg16098726 |
| .0018 | 1.30 | .20 |
| cg14423778 |
| −.0064 | −2.96 | .0052 |
| cg05294455 |
| .010 | 4.83 | 2.3×10−5 |
| cg26267561 |
| −.0029 | −1.43 | .16 |
| cg20994801 |
| −.0061 | −7.01 | 2.4×10−8 |
| cg15561986 |
| −.0029 | −3.55 | .0010 |
| cg00594952 |
| .0035 | 3.21 | .0027 |
| cg22417398 |
| . −.0033 | −4.48 | 6.7×10−5 |
| cg10652277 |
| 1.4×10−4 | .58 | .57 |
| cg16301617 |
| . −.011 | −6.86 | 3.8×10−8 |
| cg26385222 |
| .0057 | 3.42 | .0015 |
| cg00411097 |
| −.0073 | −5.63 | 1.8×10−6 |
| cg27210390 |
| .0086 | 8.92 | 7.5×10−11 |
| cg06051311 |
| −.011 | −8.08 | 8.8×10−10 |
| cg09244244 |
| −.0025 | −1.53 | .13 |
Δβ per week represents the average increase in β-value associated with each additional week of GA.